MarketCrew › Terminal › KMB
KMB — Kimberly-Clark Corporation (Stock)
Price: $104.07
· 1 day: +4.69% · 5 days: +6.48% · 1 month: +5.46% · YTD: +3.15%
As of 2026-10-15 20:00 UTC.
52-week range: $92.42 – $123.09 (currently at 38% of the range).
The brief
KMB is in an uptrend, momentum firm. $106.09 is the level overhead; $102.93 the first support below.
6 of 6 technical checks lean bullish.
Price vs 50-day: above Price vs 200-day: above 50d vs 200d avg: above MACD: bullish RSI momentum: 67 5-day tape: +6.5%
Trend Uptrend · above 50-day & 200-day Momentum RSI 66.81 · neutral · MACD bullish Trend strength ADX 24.6 · developing Location +1.1% vs 50-day MA 52-week range -14% from high · +12% from low Volatility ATR 2.2 · ~2.1%/day
Key levels
Level Type Distance
$106.09 (resistance) swing zone 1.94% $112.09 (resistance) swing zone 7.71% $121.44 (resistance) 52w high 16.69%
$102.93 (support) sma 50 -1.1% $102.48 (support) sma 200 -1.53% $100.1 (support) swing zone -3.81%
Indicators
RSI (14) 66.81 MACD -0.6319
ADX (14) 24.6 ATR (14) 2.2
50-day average $102.93 200-day average $102.48
Next earnings: 2026-11-05.
Latest KMB news
Stocks making the biggest moves midday: CoreWeave, Salesforce, Rocket Lab, Kimberly-Clark & more — Stock markets showed mixed performance in midday trading, with semiconductors declining sharply as the VanEck Semiconductor ETF fell 2% for its eighth consecutive losing day, while software companies and consumer staples (CNBC, 2026-10-15) KIMBERLY CLARK CORP — Form 8-K: 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits — ```json
{
"summary": "Kimberly-Clark Corporation filed Form 8-K on October 15, 2026, disclosing results of operations and financial condition along with regulatory fair disclosure information. The filing includes finan (SEC EDGAR, 2026-10-15) Dow Jones Top Company Headlines at 1 PM ET: JPMorgan, Goldman Profit Jumps as Banks Kick Off Earnings | J&J ... — Major financial institutions JPMorgan and Goldman Sachs reported significant third-quarter profit increases, launching the earnings season with mixed results across Wall Street. UnitedHealth Group demonstrated a strong t (Morningstar, 2026-10-13) Jim Cramer bucks all the stock market negativity with 3 buy recommendations — Jim Cramer maintained a bullish stance on Tuesday despite broad market negativity, recommending three stocks: Goldman Sachs, Wells Fargo, and Johnson & Johnson. Goldman Sachs shares rose modestly after beating earnings e (CNBC, 2026-10-13) We're adding to a consumer staples stock in advance of a big catalyst — Jim Cramer's Charitable Trust is increasing its Kimberly-Clark position by 85 shares at approximately $97 per share, raising the portfolio weighting from 1.25% to 1.5% and bringing total holdings to 600 shares. The inves (CNBC, 2026-10-13) KIMBERLY CLARK CORP — Form 8-K: 8.01 Other Events; 9.01 Financial Statements and Exhibits — ```json
{
"summary": "Kimberly Clark Corporation filed a Form 8-K with the Securities and Exchange Commission on October 13, 2026, disclosing other events and financial statements/exhibits. The filing indicates disclos (SEC EDGAR, 2026-10-13) Stocks saw new highs and big declines: How the volatile AI trade moved last week's market — U.S. stock markets experienced significant volatility last week, with the S&P 500 gaining 1.2% to close above 7,800 for the first time while the Nasdaq added 0.6%, driven by competing narratives in the AI sector. SpaceX (CNBC, 2026-10-10) Here's a rapid-fire update on our 33-stock portfolio, including Cramer's 6 favorites to buy — Jim Cramer and the CNBC Investing Club portfolio team reviewed their 33-stock portfolio at their September monthly meeting, highlighting six core buy recommendations: Kimberly-Clark, Bank of New York, Intel, Micron, Meta (CNBC, 2026-10-10)
Explore more
Interactive KMB chart and analyst chat ·
Market terminal — movers, signals and news ·
Use MarketCrew inside Claude ·
Use MarketCrew inside ChatGPT ·
Top gainers today ·
52-week highs
MarketCrew provides automated, informational market analysis — research & education,
not investment advice or a recommendation to buy or sell any security. © MarketCrew ·
Privacy · Terms